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bevacizumab (10 mg/kg every 2 weeks) and IFN (3 MIU thrice weekly) until disease progression. Descriptive comparisons with AVOREN patients having favourable/intermediate MSKCC scores treated with bevacizumab plus IFN (9 MIU) were made. Primary end points were grade ≥3 IFN-associated adverse events (AEs) and progression-free survival (PFS). All grade ≥3 AEs and bevacizumab/IFN-related grade 1-2 AEs occurring from first administration until 28 days after last treatment were reported.
Results: A total of 146 patients were treated; the median follow-up was 29.4 months. Any-grade and grade ≥3 IFNassociated AEs occurred in 53.4% and 10.3% of patients, respectively. The median PFS and overall survival were 15.3 [95% confidence interval (CI): 11.7-18.0] and 30.7 months (95% CI: 25.7-not reached), respectively. The ORR was 28.8%.
Conclusions:
Compared with a historical control AVOREN subgroup, low-dose IFN with bevacizumab resulted in a reduction in incidence rates of IFN-related AEs, without compromising efficacy [NCT00796757] . Key words: renal cell carcinoma, angiogenesis, bevacizumab, immunotherapy, interferon, VEGF introduction Most patients with metastatic renal cell carcinoma (mRCC) present with metastases that are not amenable to surgical removal and for which chemotherapy provides, at best, modest benefits [1] [2] [3] . Cytokines, in particular interferon-α (IFN), prolong progression-free survival (PFS) and overall survival (OS) in mRCC patients [4, 5] ; however, the use of IFN is often limited by toxicity, most commonly fatigue and asthenia [6] [7] [8] [9] . Lower-dose IFN (from 5 MU/day to 0.5 MU b.i.d.) is an option for some patients, improving tolerability and quality of life while maintaining efficacy [10, 11] .
Bevacizumab, a humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF)-A, is the only targeted agent that has been safely combined with other active agents in mRCC and significantly improves PFS when combined with IFN in patients with previously untreated mRCC [6, 12] . In the double-blind Avastin and Roferon in Renal Cell Carcinoma (AVOREN) trial, the combination of bevacizumab with IFN [9 MIU three times a week (tiw)] improved PFS [median of 10.2 versus 5.4 months; hazard ratio (HR) 0.63; P = 0.0001] and the objective response rate (ORR, 30.6% versus 12.4%; P = 0.0001) compared with IFN plus placebo [12] . In the Cancer and Leukemia Group B (CALGB) 90 206 study, an open-label mRCC trial, the addition of bevacizumab to IFN (9 MIU tiw) significantly improved both PFS (median of 8.5 versus 5.2 months; HR 0.71; P < 0.0001) and ORR (25.5% versus 13.1%; P < 0.0001) [6] . A trend towards OS improvement in both trials' combination arms was not statistically significant, possibly due to the availability of subsequent-line treatments unavailable when these studies were designed [6, [12] [13] [14] .
The most commonly reported grade ≥3 adverse events (AEs) in the bevacizumab plus IFN treatment arms in these studies were IFN-related, including fatigue, asthenia, anorexia, and neutropenia [6, 15] . IFN dose reduction was permitted in both trials and was associated with a reduction in grade 3/4 AEs in a retrospective analysis of AVOREN data, with improved efficacy in the bevacizumab plus IFN arm being maintained relative to IFN plus placebo (HR 0.63, P = 0.0026) [16] .
The Bevacizumab and Low-Dose Interferon (BEVLiN) trial prospectively evaluated the safety and efficacy of bevacizumab plus low-dose IFN (3 MIU tiw) 
procedures
Patients received intravenous bevacizumab at 10 mg/kg every 2 weeks (q2w) and subcutaneous IFN at 3 MIU tiw until disease progression, unacceptable toxicity, or consent withdrawal. Patients were followed until death or for 2 years after the enrolment of the last patient, whichever occurred first.
The co-primary end points were PFS and safety, specifically grade ≥3 IFN-associated AEs (fatigue, asthenia, depression, anorexia, influenza-like illness, pyrexia, nausea, vomiting, chills, and malaise) evaluated using the National Cancer Institute Common Terminology Criteria for AEs v 3.0. All grade ≥3 AEs and bevacizumab/IFN-related grade 1-2 AEs occurring from first administration until 28 days after last treatment were reported. Secondary end points were OS, investigator-assessed ORR (according to RECIST), grade 3-5 AEs, overall AEs, and serious AEs (SAE).
Patients were assessed for safety end points at treatment start, q2w thereafter until disease progression, and every 3 months during the followup. AEs of special interest were those associated with VEGF-A-targeted therapy, including hypertension, proteinuria, wound-healing complications, gastrointestinal perforation, haemorrhage, arterial and venous thromboembolic events, congestive heart failure, and reversible posterior leukoencephalopathy syndrome. Tumour assessments were conducted at baseline, every 8 weeks until week 32, and every 12 weeks thereafter until disease progression. A data monitoring committee reviewed safety data collected during the trial on an ongoing basis. One planned interim efficacy analysis was carried out once baseline assessments of the entire study population were completed. The AVOREN design was described previously [12] . To ensure similar definitions across studies, PFS was defined as the interval from date of the first post-baseline visit to the date of disease progression or death from any cause, whichever occurred first. OS was defined as the interval from the date of the first post-baseline visit until the date of death from any cause. Patients without an event were censored at the date of the last follow-up or date of last study drug administration. The median PFS and OS values and 95% confidence intervals (CIs) were calculated using the Kaplan-Meier methods.
A sample size of 140 patients was based on the assumptions of a 30% reduction in the incidence of specific IFN-related AEs (grade ≥3) and a similar median PFS compared with AVOREN, on an exploratory basis. A historical, solely descriptive comparison with the AVOREN trial was made without formal statistical comparisons between study results using P-values or HRs.
results

Bevacizumab and Low-Dose Interferon
Between December 2008 and February 2010, 147 patients were enrolled at 39 sites in 12 countries; 146 received study treatment. At the data cutoff date, 5 February 2012, the median follow-up was 29.4 months (range, 1.5-35.4 months). Sixty patients were alive, 61 had died, 4 were not followed until the cutoff date, 7 were lost to follow-up, and 15 had withdrawn from the trial. Baseline characteristics for BEVLiN patients are shown (Table 1) . Patients received a median of 22.5 cycles of bevacizumab and 132 doses of IFN (supplementary Table S1 , available at Annals of Oncology online); the median duration of treatment was10.0 months (range 2.8-20.7 months). The overall incidence rates of any-grade AEs, grade ≥3 AEs, and SAEs were 84.2%, 42.5%, and 17.8%, respectively (Table 2) . Any-grade IFN-associated AEs and grade ≥3 IFN-associated AEs were reported in 53.4% and 10.3% of patients, respectively. AEs contributed to temporary IFN interruption in 24.0% of patients.
The ORR among patients with measurable disease (n = 139) at baseline was 28.8% (95% Pearson-Clopper CI 21.4-37.1). The median PFS in the ITT population was 15.3 months (95% CI: 11.7-18.0), with an estimated PFS rate of 58.2% and 28.9% at 12 and 24 months, respectively (Table 3, Figure 1 ). The median OS was 30.7 months (95% CI: 25.7-not reached). A total of 32.9% of patients received anti-neoplastic therapy after disease progression (supplementary Table S1 , available at Annals of Oncology online). The median PFS was 10.5 months (95% CI: 10.1-12.9), and 12-and 24-month PFS rates were 47.6% and 11.0%, respectively ( Table 3 ). The median OS was 25.8 months (95% CI: 22.7-29.4).
discussion
The modified combination regimen in the BEVLiN trial appeared to allow for increased exposure to both bevacizumab and IFN. The median number of bevacizumab cycles (22.5 versus 18.0) and IFN doses (132 versus 109) was higher in BEVLiN than in the AVOREN trial. Furthermore, the BEVLiN regimen was associated with fewer temporary interruptions and permanent discontinuations due to AEs.
The use of IFN is often limited by toxicity, most commonly fatigue and asthenia [6] [7] [8] [9] , and IFN-associated AEs may be increased with the concomitant administration of bevacizumab [12] . In BEVLiN patients, the incidence rates of grade ≥3 overall and IFN-associated AEs were lower by ∼18% and 17%, respectively, compared with the AVOREN subgroup. Incidence rates of SAEs were also markedly lower in BEVLiN, with 95% CIs mostly not overlapping. Moreover, despite the longer duration of IFN treatment, the incidence of any-grade fatigue/ asthenia, pyrexia, influenza-like illness, depression, anorexia, and nausea was also lower in BEVLiN. These observations support previous reports that IFN-associated toxic effects are dose-related [17, 18] and prospectively demonstrate that reducing the IFN dose substantially improves the safety profile of the bevacizumab plus IFN regimen.
Approximately 60% of patients in both studies reported a ≥1 bevacizumab (VEGF-A)-blockade-related AE of any grade, hypertension, proteinuria, and bleeding being the most common. The overall incidence of grade ≥3 VEGF-A-blockadeassociated AEs was similar between the two populations, although a higher frequency of grade ≥3 hypertension (15.8% versus 6.4%) was observed in BEVLiN patients. The longer duration of bevacizumab treatment may have contributed to the higher occurrence of some AEs, including grade ≥3 hypertension and any-grade proteinuria [19, 20] . Importantly, there was no indication that either PFS or OS outcomes in BEVLiN patients were inferior to those observed in the comparative AVOREN subgroup. The median PFS (15.3 months) and OS (30.7 months) in BEVLiN patients compared well with other targeted agents used in the first-line setting of mRCC patients with MSKCC favourable/ intermediate scores [7, 21, 22] . The observation that nearly 30% of patients were alive and progression-free at 2 years demonstrated that a substantial subset of patients experienced long-term clinical benefit from the modified regimen. Potential factors contributing to treatment efficacy in the BEVLiN study include the longer exposure to both bevacizumab and IFN, taking the advantage of the possible synergistic anti-angiogenic effect of low-dose IFN [8, 16] . A complete response rate of 2% is remarkably similar in BEVLiN, AVOREN, and earlier trials of IFN [10] . The anecdotal experience with these rare patients indicates that complete response is durable on prolonged IFN therapy. The potential contribution of bevacizumab and the optimal duration of bevacizumab therapy in patients experiencing complete response remain speculative. A lower proportion of patients who received subsequent therapies (32.9% in BEVLiN compared with 46.0% in the bevacizumab plus IFN comparator subgroup in AVOREN) reflects the fact that 30.8% of patients did not progress at the time of analysis as well as the limited availability of targeted agents in some participating countries.
Inherent in the BEVLiN trial design were limitations based primarily on using a historical control population as the safety and efficacy comparator. Descriptive analyses were conducted among BEVLiN patients and those in the AVOREN subgroup. Although baseline characteristics and were generally similar in both studies, since AVOREN preceded BEVLiN by ∼5 years, incremental experience with the administration of bevacizumab and management of complications, differences in the availability and use of treatment modalities, best supportive care upon progressive disease, and potentially unobserved latent variables ('trial effects') [23] may explain an improvement in outcomes. In fact, the results of the BEVLiN trial are remarkably similar to the efficacy of bevacizumab plus IFN recently reported in the Torisel and Avastin (TORAVA) trial [24] .
In conclusion, data from the present, multinational, phase II trial further support the hypothesis that, in patients with previously untreated mRCC, the use of bevacizumab in combination with low-dose IFN results in a more favourable safety profile, with similar efficacy, compared with bevacizumab plus high-dose IFN. These results suggest that the regimen of bevacizumab plus low-dose IFN (3 MIU) is a viable option for the first-line treatment of patients with clear-cell mRCC who have favourable or intermediate MSKCC scores.
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